ABSTRACT
We report a metaproteomic analysis of the gut microbiota of eight infants with cystic fibrosis, during the first year of life. This is the first study in this disease that uses metaproteomics to analyze stool samples from patients at such a young age.
ABSTRACT
Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage IIII resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available (AU)
Subject(s)
Humans , Skin Neoplasms/diagnosis , Skin Neoplasms/therapy , Melanoma/diagnosis , Melanoma/therapy , Neoplasm Staging , Societies, Medical , SpainABSTRACT
Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I-III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available.
Subject(s)
Melanoma/pathology , Melanoma/therapy , Skin Neoplasms/pathology , Skin Neoplasms/therapy , Biopsy , Brain Neoplasms/secondary , Brain Neoplasms/therapy , Chemotherapy, Adjuvant/methods , Follow-Up Studies , Humans , Immunotherapy/methods , Lymph Node Excision , Medical Oncology , Melanoma/diagnosis , Melanoma/genetics , Molecular Targeted Therapy/methods , Neoplasm Staging , Proto-Oncogene Proteins B-raf/analysis , Proto-Oncogene Proteins B-raf/genetics , Radiotherapy, Adjuvant , Skin Neoplasms/diagnosis , Skin Neoplasms/genetics , Societies, Medical , SpainABSTRACT
PURPOSE: Intestinal dysbiosis has emerged as a biomarker of response to immune checkpoint inhibitors (ICIs). It can be caused by antibiotics, although it may also result from the use of other drugs that have been studied to a lesser extent. The objective of our study was to analyze the association between the use of potentially dysbiosis-related drugs and survival in patients treated with ICIs in the clinical practice. MATERIALS AND METHODS: A retrospective, multicenter, cohort study was conducted. Clinicopathological variables were collected and the concomitant use of drugs was analyzed. A descriptive analysis of variables and overall survival, estimated by the Kaplan-Meier method, was performed, and association with various independent variables was assessed using Cox regression. RESULTS: We included 253 patients, mainly with non-small cell lung cancer and melanoma. The most commonly used drugs were acid reducers, prescribed to 55.3% of patients, followed by corticosteroids (37.9%), anxiolytic drugs (35.6%), and antibiotics (20.5%). The use of acid reducers (9 vs. 18 months, P < .0001), antibiotics (7 vs. 15 months, P < .017), anxiolytic drugs (8 vs. 16 months, P < .015), and corticosteroids (6 vs. 19 months, P < .00001) was associated with poorer overall survival. Furthermore, the greater the number of drugs used concomitantly with ICIs, the higher the risk of death (1 drug: hazard ratio, 1.88; CI 95%, 1.07-3.30; 4 drugs: hazard ratio, 4.19; CI9 5%, 1.77-9.92; P < .001). CONCLUSION: Response to ICIs may be influenced by the use of drugs that lead to intestinal dysbiosis. Although a confirmatory prospective controlled study is required, our findings should be taken into account when analyzing ICI efficacy.
Subject(s)
Carcinoma, Non-Small-Cell Lung/drug therapy , Dysbiosis/chemically induced , Immune Checkpoint Inhibitors/therapeutic use , Lung Neoplasms/drug therapy , Melanoma/drug therapy , Adrenal Cortex Hormones/adverse effects , Adult , Aged , Aged, 80 and over , Antacids/adverse effects , Anti-Anxiety Agents/adverse effects , Carcinoma, Non-Small-Cell Lung/mortality , Female , Humans , Lung Neoplasms/mortality , Male , Melanoma/mortality , Middle Aged , Retrospective StudiesABSTRACT
Cancer is the leading social and healthcare problem of the twenty-first century. The aim of primary prevention is to decrease the incidence of cancer by avoiding the known causes and risk factors. Nevertheless, it has been estimated that cancer diagnoses could be halved through primary prevention measures. A comprehensive review of the scientific evidence regarding the main carcinogens and risk factors and primary prevention recommendations have been put forth based on this evidence. The GRADE scale has been used to classify the grade of evidence. We present the scientific evidence and recommendations for primary prevention of the major modifiable risk factors: smoking, alcohol, diet, obesity, physical activity, occupational and environmental factors, ultraviolet radiation, infections, and socioeconomic factors. Primary prevention is a simple, effective means to lower the incidence of cancer. Preventive measures must be circulated in the fight against cancer.
Subject(s)
Neoplasms/prevention & control , Practice Guidelines as Topic/standards , Primary Prevention , Clinical Trials as Topic , Disease Management , Humans , Neoplasms/etiology , Prognosis , Risk Factors , Societies, MedicalABSTRACT
Cancer is the leading social and healthcare problem of the twenty-first century. The aim of primary prevention is to decrease the incidence of cancer by avoiding the known causes and risk factors. Nevertheless, it has been estimated that cancer diagnoses could be halved through primary prevention measures. A comprehensive review of the scientific evidence regarding the main carcinogens and risk factors and primary prevention recommendations have been put forth based on this evidence. The GRADE scale has been used to classify the grade of evidence. We present the scientific evidence and recommendations for primary prevention of the major modifiable risk factors: smoking, alcohol, diet, obesity, physical activity, occupational and environmental factors, ultraviolet radiation, infections, and socioeconomic factors. Primary prevention is a simple, effective means to lower the incidence of cancer. Preventive measures must be circulated in the fight against cancer
No disponible
Subject(s)
Humans , Primary Prevention/methods , Healthy Lifestyle , Neoplasms/prevention & control , Practice Patterns, Physicians' , Risk Factors , Tobacco Use Disorder/prevention & control , Tobacco Use Cessation , Alcohol Drinking/adverse effects , Obesity/complications , Environmental Exposure/adverse effectsABSTRACT
A sentence under 'Results' heading in the Abstract section was published incorrectly. The correct sentence should read as follows.
ABSTRACT
Background: We hypothesized that the abundance of PD1 mRNA in tumor samples might explain the differences in overall response rates (ORR) observed following anti-PD1 monotherapy across cancer types. Patients and methods: RNASeqv2 data from 10 078 tumor samples representing 34 different cancer types was analyzed from TCGA. Eighteen immune-related gene signatures and 547 immune-related genes, including PD1, were explored. Correlations between each gene/signature and ORRs reported in the literature following anti-PD1 monotherapy were calculated. To translate the in silico findings to the clinical setting, we analyzed the expression of PD1 mRNA using the nCounter platform in 773 formalin-fixed paraffin embedded (FFPE) tumor samples across 17 cancer types. To test the direct relationship between PD1 mRNA, PDL1 immunohistochemistry (IHC), stromal tumor-infiltrating lymphocytes (sTILs) and ORR, we evaluated an independent FFPE-based dataset of 117 patients with advanced disease treated with anti-PD1 monotherapy. Results: In pan-cancer TCGA, PD1 mRNA expression was found strongly correlated (r > 0.80) with CD8 T-cell genes and signatures and the proportion of PD1 mRNA-high tumors (80th percentile) within a given cancer type was variable (0%-84%). Strikingly, the PD1-high proportions across cancer types were found strongly correlated (r = 0.91) with the ORR following anti-PD1 monotherapy reported in the literature. Lower correlations were found with other immune-related genes/signatures, including PDL1. Using the same population-based cutoff (80th percentile), similar proportions of PD1-high disease in a given cancer type were identified in our in-house 773 tumor dataset as compared with TCGA. Finally, the pre-established PD1 mRNA FFPE-based cutoff was found significantly associated with anti-PD1 response in 117 patients with advanced disease (PD1-high 51.5%, PD1-intermediate 26.6% and PD1-low 15.0%; odds ratio between PD1-high and PD1-intermediate/low = 8.31; P < 0.001). In this same dataset, PDL1 tumor expression by IHC or percentage of sTILs was not found associated with response. Conclusions: Our study provides a clinically applicable assay that links PD1 mRNA abundance, activated CD8 T-cells and anti-PD1 efficacy.
Subject(s)
Antineoplastic Agents, Immunological/therapeutic use , CD8-Positive T-Lymphocytes/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Lymphocytes, Tumor-Infiltrating/drug effects , Neoplasms/metabolism , Programmed Cell Death 1 Receptor/metabolism , RNA, Messenger/metabolism , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , CD8-Positive T-Lymphocytes/immunology , Cohort Studies , Female , Follow-Up Studies , Humans , Lymphocytes, Tumor-Infiltrating/immunology , Male , Middle Aged , Neoplasms/drug therapy , Neoplasms/immunology , Neoplasms/pathology , Prognosis , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Programmed Cell Death 1 Receptor/genetics , RNA, Messenger/genetics , Survival RateABSTRACT
Introduction: This study aimed to describe the efficacy of fulvestrant 500 mg in postmenopausal women with estrogen receptor (ER)-positive advanced/metastatic breast cancer who had disease progression after receiving anti-estrogen therapy in clinical practice, getting real-world data. Materials and methods: Multicenter, retrospective, observational study conducted in Spain. Postmenopausal women with locally advanced/metastatic ER-positive breast cancer who received treatment with fulvestrant 500 mg after progression with a previous anti-estrogen therapy were eligible. The primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS), clinical benefit rate (CBR), duration of clinical benefit (DoCB), and safety profile. Results: A total of 263 women were evaluated (median age, 65.8 years). At a median follow-up of 21.5 months, median PFS and OS were 10.6 and 43.2 months, respectively. PFS according to 1st, 2nd, 3rd, and ≥ 4th lines were 11.5, 10.6, 9.9, and 8.5 months, respectively (p = 0.0245). PFS in patients with visceral involvement was 10 months vs 10.6 months in patients without visceral involvement (p = 0.6604), 9.6 months in patients with high Ki67 vs 10 months in patients with low Ki67 (p = 0.7224), and 10.2 months in HER2+ patients vs 10.3 months in HER2− patients (p = 0.6809). The CBR was 56.5% and the DoCB was 18.4 months. The most frequently adverse events were injection site pain (10.3%) and musculoskeletal disorders (7.6%). Conclusions: Fulvestrant 500 mg administered in clinical practice was shown to be effective (PFS, 10.6 months; CBR, 56.5%) and well tolerated, in accordance with previous trials
No disponible
Subject(s)
Humans , Female , Breast Neoplasms/drug therapy , Carcinoma, Ductal, Breast/drug therapy , Carcinoma, Lobular/drug therapy , Breast Neoplasms/secondary , Drug Resistance, Neoplasm , Antineoplastic Agents, Hormonal/therapeutic use , Carcinoma, Ductal, Breast/pathology , Carcinoma, Lobular/pathology , Lymphatic Metastasis/pathology , Postmenopause , Retrospective Studies , Receptor, ErbB-2/geneticsABSTRACT
INTRODUCTION: This study aimed to describe the efficacy of fulvestrant 500 mg in postmenopausal women with estrogen receptor (ER)-positive advanced/metastatic breast cancer who had disease progression after receiving anti-estrogen therapy in clinical practice, getting real-world data. MATERIALS AND METHODS: Multicenter, retrospective, observational study conducted in Spain. Postmenopausal women with locally advanced/metastatic ER-positive breast cancer who received treatment with fulvestrant 500 mg after progression with a previous anti-estrogen therapy were eligible. The primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS), clinical benefit rate (CBR), duration of clinical benefit (DoCB), and safety profile. RESULTS: A total of 263 women were evaluated (median age, 65.8 years). At a median follow-up of 21.5 months, median PFS and OS were 10.6 and 43.2 months, respectively. PFS according to 1st, 2nd, 3rd, and ≥ 4th lines were 11.5, 10.6, 9.9, and 8.5 months, respectively (p = 0.0245). PFS in patients with visceral involvement was 10 months vs 10.6 months in patients without visceral involvement (p = 0.6604), 9.6 months in patients with high Ki67 vs 10 months in patients with low Ki67 (p = 0.7224), and 10.2 months in HER2+ patients vs 10.3 months in HER2- patients (p = 0.6809). The CBR was 56.5% and the DoCB was 18.4 months. The most frequently adverse events were injection site pain (10.3%) and musculoskeletal disorders (7.6%). CONCLUSIONS: Fulvestrant 500 mg administered in clinical practice was shown to be effective (PFS, 10.6 months; CBR, 56.5%) and well tolerated, in accordance with previous trials.
Subject(s)
Breast Neoplasms/drug therapy , Carcinoma, Ductal, Breast/drug therapy , Carcinoma, Lobular/drug therapy , Drug Resistance, Neoplasm , Estradiol/analogs & derivatives , Postmenopause , Aged , Antineoplastic Agents, Hormonal/therapeutic use , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/metabolism , Carcinoma, Ductal, Breast/secondary , Carcinoma, Lobular/metabolism , Carcinoma, Lobular/secondary , Estradiol/therapeutic use , Female , Follow-Up Studies , Fulvestrant , Humans , Lymphatic Metastasis , Middle Aged , Prognosis , Receptor, ErbB-2/metabolism , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Retrospective StudiesABSTRACT
Background. The programmed death (PD-1) inhibitor pembrolizumab has been recently approved for the treatment of advanced melanoma. We evaluated the clinical activity of pembrolizumab in melanoma patients treated under the Spanish Expanded Access Program. Methods. Advanced melanoma patients who failed to previous treatment lines were treated with pembrolizumab 2 mg/kg every three weeks. Patients with brain metastases were not excluded if they were asymptomatic. Data were retrospectively collected from 21 centers in the Spanish Melanoma Group. Results. Sixty-seven advanced melanoma patients were analyzed. Most patients were stage M1c (73.1%), had high LDH levels (55.2%) and had ECOG PS 1 or higher (59.7%). For cutaneous melanoma patients, median overall survival was 14.0 months; the 18-month overall survival rate was 47.1%. Overall response rate was 27%, including three patients with complete responses (6.5%). Median response duration was not reached, with 83.3% of responses ongoing (3.5 m+ to 20.4 m+). From ten patients included with brain metastases, four (40%) had an objective response, two (20%) of them achieved a complete response. Significant prognostic factors for overall survival were LDH level, ECOG PS and objective response. There were no serious adverse events. Conclusion. Although this was a heavily pretreated cohort, pembrolizumab activity at the approved dose and schedule was confirmed in the clinical setting with long-term responders, also including patients with brain metastases (AU)
No disponible
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Melanoma/drug therapy , Neoplasm Metastasis/drug therapy , Health Promotion/standards , Neoplasm Staging/methods , Retrospective Studies , Prognosis , Surveys and Questionnaires , Multivariate Analysis , Melanoma/classification , Skin Neoplasms/drug therapy , Uveal Neoplasms/drug therapyABSTRACT
Introducción: existe una relación entre la percepción de riesgo asociada al consumo de una sustancia y la probabilidad de consumirla. Objetivo: conocer la percepción de peligrosidad del consumo ocasional de tabaco convencional y electrónico en adolescentes entre 13 y 18 años escolarizados en Castilla y León (España) (curso 2014-15), así como su relación con otros factores sociodemográficos. Material y métodos: estudio descriptivo transversal con un muestreo aleatorio bietápico por conglomerados. Para calcular el tamaño de la muestra se estimó una probabilidad del 50% en todas nuestras respuestas, un margen de confianza del 95,5% y una probabilidad de error en contraste bilateral del 1,7%. Se utilizó un cuestionario estandarizado, telemático y anónimo, con preguntas análogas a las utilizadas en programas nacionales e internacionales para conocer la percepción de riesgo sobre el consumo de drogas en adolescentes. Resultados: la muestra final fue de 3311 adolescentes (media de edad 14,8 ± 1,3 años). Encontramos una elevada percepción de peligrosidad del consumo ocasional de tabaco en adolescentes (lo consideran muy peligroso el 44,2%, n = 1469). Sin embargo, el cigarrillo electrónico goza de una menor percepción de riesgo (lo consideran muy peligroso el 18,5%, n = 616), sin diferencias estadísticamente significativas en relación con la edad ni con la funcionalidad familiar. Las mujeres (odds ratio: 1,28) y los adolescentes de centros públicos (odds ratio: 1,32) presentan menor percepción de peligrosidad (p < 0,05 respectivamente). Conclusiones: los cigarrillos electrónicos podrían convertirse en una vía adicional de iniciación al tabaquismo en adolescentes por su accesibilidad, sus atractivos sabores y la baja percepción de peligrosidad asociada a su consumo en la adolescencia temprana (AU)
Introduction: research into drug consumption agrees on the relationship between the perception of the risk associated with the consumption of a substance and the probability of consuming it. Objective: To find out the perception of danger in the occasional consumption of conventional and electronic cigarettes in adolescents aged between 13 and 18 attending school in Castile & Leon (academic year 2014-2015), as well as their relation with other sociodemographic factors. Material and methods: a standardized, telematic and anonymous questionnaire was used with analogous questions to those used in national and international programmes to discover the risk perception concerning the consumption of drugs among adolescents. A descriptive, cross-sectional study with a random, two-stage cluster sample was also used. A probability of 50% was estimated in all our answers, with a confidence interval of 95.5% and an error probability in bilateral contrast of 1.7%. The final sample was made up of 3,311 adolescents (mean age 14.8±1.3 years). Results: we found a high perception of risk for the occasional consumption of tobacco among adolescents (74.3% considering it very dangerous, n = 2458). However, with the electronic cigarette there is a lower perception of risk (only 65.9% considered it to be very dangerous), with no statistically significant differences in relation to age or family functionality (p < 0.005 respectively). Women (odds ratio: 1.28) and adolescents from public centres (p ≤ 0.01 respectively) show a lower perception of danger. Conclusions: the e-cigarettes could become an additional way of initiatiating tobacco smoking in adolescents due to their accessibility, their attractive flavours and the low perception of danger associated with their consumption in early adolescence (AU)
Subject(s)
Humans , Male , Female , Adolescent , Smoking/adverse effects , Smoking/epidemiology , Tobacco Smoke Pollution/prevention & control , Risk Factors , Electronic Nicotine Delivery Systems , Electronic Nicotine Delivery Systems/statistics & numerical data , Cross-Sectional Studies , Cluster Sampling , Confidence Intervals , Odds Ratio , Surveys and QuestionnairesABSTRACT
BACKGROUND: The programmed death (PD-1) inhibitor pembrolizumab has been recently approved for the treatment of advanced melanoma. We evaluated the clinical activity of pembrolizumab in melanoma patients treated under the Spanish Expanded Access Program. METHODS: Advanced melanoma patients who failed to previous treatment lines were treated with pembrolizumab 2 mg/kg every three weeks. Patients with brain metastases were not excluded if they were asymptomatic. Data were retrospectively collected from 21 centers in the Spanish Melanoma Group. RESULTS: Sixty-seven advanced melanoma patients were analyzed. Most patients were stage M1c (73.1%), had high LDH levels (55.2%) and had ECOG PS 1 or higher (59.7%). For cutaneous melanoma patients, median overall survival was 14.0 months; the 18-month overall survival rate was 47.1%. Overall response rate was 27%, including three patients with complete responses (6.5%). Median response duration was not reached, with 83.3% of responses ongoing (3.5 m+ to 20.4 m+). From ten patients included with brain metastases, four (40%) had an objective response, two (20%) of them achieved a complete response. Significant prognostic factors for overall survival were LDH level, ECOG PS and objective response. There were no serious adverse events. CONCLUSION: Although this was a heavily pretreated cohort, pembrolizumab activity at the approved dose and schedule was confirmed in the clinical setting with long-term responders, also including patients with brain metastases.
Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents/therapeutic use , Melanoma/drug therapy , Adult , Aged , Aged, 80 and over , Disease-Free Survival , Female , Humans , Kaplan-Meier Estimate , Male , Melanoma/mortality , Middle Aged , Proportional Hazards Models , Retrospective Studies , Salvage Therapy/methods , Spain , Treatment OutcomeABSTRACT
OBJECTIVES: To examine the relationship between polymorphisms of the epidermal growth factor receptor (EGFR) pathway and toxicity in head and neck squamous cell carcinoma (HNSCC) patients treated with cetuximab. MATERIAL AND METHODS: Multicenter, retrospective, observational pilot study which included 110 patients with histologically-confirmed human papillomavirus (HPV) negative HNSCC in locally advanced stages (III-IVA-B) and who were treated with chemotherapy and radiotherapy plus cetuximab between 2003 and 2013. Genetic analyses for single nucleotide polymorphisms (SNP) in genes EGFR, CCDN1, FCGR2A, FCGR3A and KRAS-LCS6 were performed though available allelic discrimination assay and/or polymerase chain reaction-restriction fragment length polymorphism methods. RESULTS: Acneiform rash was observed in 55.5% of patients, dry skin in 45.5% and pruritus in 20.9%. A significant association with dry skin and global cetuximab-related toxicity was observed for the KRAS-LCS6 (rs61764370) variant (p<0.05); carriers of the G allele (genotypes TG+GG) in the dominant model were observed to have a decreased susceptibility of developing dry skin (OR=0.287 [95%CI=0.119-0.695]). Carriers of the A (GA+AA) allele for EGFR (rs2227983) showed a decreased risk of suffering from pruritus (OR=0.345 [0.124-0.958]). Similarly, KRAS (rs1801274) was related with lower global cetuximab-related toxicity (OR=0.266 [0.114-0.622]). CONCLUSION: This pilot study provides preliminary evidence supporting genetic variation of EGFR (rs2227983), KRAS (rs61764370) and FCGR2A (rs180127) as useful biomarkers for predicting reduced skin toxicity in HNSCC patients treated with a cetuximab-based therapy. Alternative therapeutic options should be explored for these patients.
Subject(s)
Antineoplastic Agents, Immunological/adverse effects , Carcinoma, Squamous Cell/drug therapy , Cetuximab/adverse effects , ErbB Receptors/genetics , Head and Neck Neoplasms/drug therapy , Polymorphism, Genetic , Antineoplastic Agents, Immunological/therapeutic use , Cetuximab/therapeutic use , Female , Humans , Male , Middle Aged , Spain , Squamous Cell Carcinoma of Head and NeckABSTRACT
Purpose. Head and neck cancer is a highly heterogeneous disease comprising a large number of tumors located in the cervicofacial area. This study aimed to determine the epidemiological characteristics of squamous-cell carcinomas of the head and neck in the Spanish population, and the distribution of risk factors based on tumor locations. Methods/patients. A cohort of 459 patients (75 oral cavity, 167 oro-/hypopharyngeal and 217 laryngeal cancers) recruited in 19 hospitals participating in the Spanish head and neck cancer cooperative group were included over 3 years (2012-2014). Epidemiological parameters and risk factors were obtained from a self-administered questionnaire, and tumor characteristics were obtained from clinical records. Multivariate multinomial logistic regression was used to assess factors associated with tumor location. Results. Most patients were males (88.4 %), smokers (95 %) and drinkers (76.5 %). Relative to laryngeal cancer, pharyngeal cancer and oral cancer were more common in women than men (OR 3.58, p = 0.003 and 4.33, p = 0.001, respectively); pharyngeal cancer was more associated with rural environment (OR 1.81, p = 0.007) and weekly alcohol intake (10-140 g: OR 2.53, p = 0.012; 141-280 g: OR 2.47, p = 0.023; >280 g: OR 3.20, p = 0.001) and less associated with pack-years of smoking (21-40 packs: OR 0.46, p = 0.045; 41-70 packs: OR 0.43, p = 0.023; ≥71 packs: OR 3.20, p = 0.015). Conclusions. The distribution of these tumors differs between the sexes, with a higher proportion of oral cavity and pharyngeal tumors in women than in men. Oro-/hypopharyngeal cancers were more strongly associated with rural areas and with alcohol consumption, although less strongly associated with smoking than laryngeal tumors (AU)
No disponible
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Head and Neck Neoplasms/diagnosis , Head and Neck Neoplasms/epidemiology , Carcinoma, Squamous Cell/diagnosis , Risk Factors , Laryngeal Neoplasms/complications , Cohort Studies , Multivariate Analysis , Surveys and QuestionnairesABSTRACT
PURPOSE: Head and neck cancer is a highly heterogeneous disease comprising a large number of tumors located in the cervicofacial area. This study aimed to determine the epidemiological characteristics of squamous-cell carcinomas of the head and neck in the Spanish population, and the distribution of risk factors based on tumor locations. METHODS/PATIENTS: A cohort of 459 patients (75 oral cavity, 167 oro-/hypopharyngeal and 217 laryngeal cancers) recruited in 19 hospitals participating in the Spanish head and neck cancer cooperative group were included over 3 years (2012-2014). Epidemiological parameters and risk factors were obtained from a self-administered questionnaire, and tumor characteristics were obtained from clinical records. Multivariate multinomial logistic regression was used to assess factors associated with tumor location. RESULTS: Most patients were males (88.4 %), smokers (95 %) and drinkers (76.5 %). Relative to laryngeal cancer, pharyngeal cancer and oral cancer were more common in women than men (OR 3.58, p = 0.003 and 4.33, p = 0.001, respectively); pharyngeal cancer was more associated with rural environment (OR 1.81, p = 0.007) and weekly alcohol intake (10-140 g: OR 2.53, p = 0.012; 141-280 g: OR 2.47, p = 0.023; >280 g: OR 3.20, p = 0.001) and less associated with pack-years of smoking (21-40 packs: OR 0.46, p = 0.045; 41-70 packs: OR 0.43, p = 0.023; ≥71 packs: OR 3.20, p = 0.015). CONCLUSIONS: The distribution of these tumors differs between the sexes, with a higher proportion of oral cavity and pharyngeal tumors in women than in men. Oro-/hypopharyngeal cancers were more strongly associated with rural areas and with alcohol consumption, although less strongly associated with smoking than laryngeal tumors.
Subject(s)
Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/pathology , Head and Neck Neoplasms/epidemiology , Head and Neck Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Alcohol Drinking/adverse effects , Carcinoma, Squamous Cell/etiology , Female , Head and Neck Neoplasms/etiology , Humans , Male , Middle Aged , Risk Factors , Smoking/adverse effects , Spain/epidemiology , Squamous Cell Carcinoma of Head and NeckABSTRACT
The characterization of biomolecular interactions is essential when designing novel biosensors, since the interaction between the bioreceptor and the ligand determines important biosensing parameters such as sensitivity and selectivity. In this paper we study the interaction of the trimeric Ara h 1 protein with a monoclonal anti-Ara h 1 antibody by means of magnetic force-induced dissociation. The proteins were bound to magnetic particles and polystyrene surfaces by EDC/NHS reaction chemistry and by physisorption, respectively. Two different molecular configurations have been investigated, with either the Ara h 1 protein on the particles or the Ara h 1 protein on the polystyrene surface. A model with a Gaussian distribution of energy barriers for dissociation gives an adequate description for the measured multi-exponential decays. We hypothesize that distributions of molecular orientations as well as experimentally induced variations may underlay the observed distributions. The two molecular configurations show a different peak value of the energy distribution. Similarly, SPR experiments for two distinct configurations (either Ara h 1 protein on the surface, or anti-Ara h 1 antibody on the surface) also show clear differences in dissociation behavior. We hypothesize that the multivalency of the involved molecules leads to different modes of binding. The results of this work highlight the importance of molecular inhomogeneities when studying the interaction processes of biomolecular complexes.
Subject(s)
Allergens/immunology , Antibodies, Monoclonal/immunology , Immunologic Techniques , Plant Proteins/immunology , Arachis/immunology , Biosensing Techniques , Models, Theoretical , Surface Plasmon ResonanceABSTRACT
El enfisema lobar congénito suele tratarse quirúrgicamente. Actualmente, se recomienda el término de hiperinsuflación lobar congénita, ya que se trata de un tejido pulmonar anatomopatológicamente sano, motivo por el que el manejo conservador puede ser una alternativa válida. Se presentan 4 casos diagnosticados de hiperinsuflación lobar congénita en los que se optó por el tratamiento conservador debido a su estabilidad clínica y en los que la evolución de los mismos ha sido satisfactoria con normalidad radiológica progresiva
Congenital lobar emphysema used to be treated surgically. Congenital lobar hyperinflation is the currently recommended term, as it involves pathologically healthy lung tissue, which is why conservative management may be an option. Four cases of diagnosed congenital lobar hyperinflation are presented in which conservative treatment was chosen due to their clinical stability. Their outcome has been satisfactory with progressively normal radiology
Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Pulmonary Emphysema/congenital , Bronchi/abnormalities , Respiratory System Abnormalities , Lung/abnormalities , Organ Sparing Treatments/methods , Asphyxia Neonatorum/etiologyABSTRACT
Congenital lobar emphysema used to be treated surgically. Congenital lobar hyperinflation is the currently recommended term, as it involves pathologically healthy lung tissue, which is why conservative management may be an option. Four cases of diagnosed congenital lobar hyperinflation are presented in which conservative treatment was chosen due to their clinical stability. Their outcome has been satisfactory with progressively normal radiology.
Subject(s)
Pulmonary Emphysema/congenital , Female , Humans , Infant , Infant, Newborn , Male , Pulmonary Emphysema/therapyABSTRACT
Introducción: Las neumonías recurrentes (NR) se definen como la presencia de infiltrados radiológicos que recurren después de una resolución completa del proceso neumónico inicial. A pesar de que son un motivo frecuente de demanda de asistencia en las unidades de neumología infantil, existen pocos estudios que evalúen su incidencia real. Pacientes y métodos: Estudio descriptivo de los pacientes diagnosticados de NR en la Unidad de Neumología Infantil del Hospital Regional Universitario «Carlos Haya» (Málaga), tanto ambulatoriamente como en planta de hospitalización, durante un periodo de 1 año. Se procedió a la elaboración de una base de datos a través de un cuestionario de evaluación. Resultados: Se incluyó a 157 pacientes con diagnóstico de NR, el 61,8% de los cuales fueron atendidos en consultas externas y el 37,6% en planta de hospitalización. Se estableció un diagnóstico etiológico en el 97,5% de los casos, y los más frecuentes fueron el asma (37,2%), la fibrosis quística (23,7%) y el síndrome aspirativo (11,5%). En el 75,3% de las recurrencias la localización fue variable, en el 14,3% única y en el 9,7% tuvo una distribución intersticial. Conclusiones: La historia clínica y la exploración física detalladas, junto con las características radiológicas, orientan el diagnóstico de las NR en la mayoría de los casos. Elegiremos eventuales pruebas complementarias en función de la localización de las recurrencias, la edad del paciente y la prevalencia de las distintas patologías. En nuestro estudio, de forma global, las causas subyacentes de NR más frecuentes fueron el asma, la fibrosis quística y los síndromes aspirativos crónicos (AU)
Background: Recurrent pneumonia (RP) is defined as the presence of radiographic infiltrates recurring after complete resolution of initial pneumonic process. Although it is a common cause of demand for assistance in pediatric respiratory units, there are few studies to evaluate the actual impact. Patients and methods: A descriptive study of patients diagnosed with RP in the Pediatric Respiratory Unit of Carlos Haya's University Hospital (Málaga), both ambulatory and in hospital wards during a period of one year. We proceeded to the development of a database through an evaluation questionnaire. Results: We collected 157 patients with RP, 61.8% attended in outpatient clinics and 37.6% in hospital wards. Etiological diagnosis was established in 97.5% of cases, the most frequent asthma (37.2%), cystic fibrosis (23.7%) and aspiration syndrome (11.5%). In 75.3% of recurrences location was variable, 14.3% were unique location and 9.7% had interstitial distribution. Conclusions: The clinical history and detailed physical examination, with radiographic features, guide the diagnosis of RP in most cases. Choose of additional tests depends on the location of recurrences, the patient's age and the prevalence of the diseases. In our study, overall, the most common underlying causes of RP were asthma, cystic fibrosis and chronic aspiration syndromes (AU)